[
    [
        {
            "time": "",
            "original_text": "中泰证券---贝达药业：业绩表现亮眼，创新管线不断丰富【公司研究】",
            "features": {
                "keywords": [
                    "贝达药业",
                    "业绩表现",
                    "创新管线",
                    "丰富"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中泰证券---贝达药业：业绩表现亮眼，创新管线不断丰富【公司研究】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：争做国产创新药研发的标杆企业",
            "features": {
                "keywords": [
                    "贝达药业",
                    "国产创新药",
                    "标杆企业"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业：争做国产创新药研发的标杆企业",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558)：恩沙替尼与埃克替尼研究数据亮眼 Q4超预期",
            "features": {
                "keywords": [
                    "贝达药业",
                    "恩沙替尼",
                    "埃克替尼",
                    "研究数据",
                    "Q4",
                    "超预期"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)：恩沙替尼与埃克替尼研究数据亮眼 Q4超预期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558)：业绩表现亮眼 创新管线不断丰富",
            "features": {
                "keywords": [
                    "贝达药业",
                    "业绩表现",
                    "创新管线",
                    "丰富"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)：业绩表现亮眼 创新管线不断丰富",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "国金证券---贝达药业：公司业绩稳步增长，恩莎替尼一线数据更新【公司研究】",
            "features": {
                "keywords": [
                    "贝达药业",
                    "业绩增长",
                    "恩莎替尼",
                    "一线数据",
                    "更新"
                ],
                "sentiment_score": 0.88,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券---贝达药业：公司业绩稳步增长，恩莎替尼一线数据更新【公司研究】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]